What is LONA's current stock price?

LONA (LeonaBio, Inc.) is currently trading at $10.33 with a market cap of $40.7M.

What sector is LeonaBio, Inc. in?

LeonaBio, Inc. (LONA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is LONA a good stock to buy?

Analysts have a Buy consensus on LONA with a price target of $10.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

LONA LeonaBio, Inc.

Healthcare

$10.33+2.58%ClosedMarket Cap: $40.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.99

P/S

0.00

EV/EBITDA

-0.08

DCF Value

$15.07

FCF Yield

-127.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-381.0%

ROA

-180.8%

ROIC

-168.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-32.9M	$—
Q4 null	$0.00	$-82.9M	$—
FY null	$0.00	$-105.6M	$—
Q3 null	$0.00	$-6.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell

MizuhoOutperform

2026-02-19

Trading Activity

Insider Trades

View All

Silverman Peter B.director

SellThu May 07

Silverman Peter B.

SellThu May 07

Holles Natalie C.director

SellThu May 07

Holles Natalie C.

SellThu May 07

Callori Freddirector

SellThu May 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.98

LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Peers

ICU